Merrimack Pharma Cutting Jobs Again After Shelving Third Cancer Drug In Year

 
• By Sten Stovall

Merrimack Pharmaceuticals is ending development of its lead drug MM-310 because of safety concerns, triggering a fresh round of job cuts at the troubled Cambridge, Massachusetts-based biotech.

Crisis
MM-310's Failure Deepens Crisis At Merrimack Pharma • Source: Shutterstock

More from Clinical Trials

More from R&D